Clinical trial
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
NCT02776072 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
- Lead sponsor
- Biogen
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2016
- Completion date
- December 31, 2016
- Enrollment
- 2,978 (actual)
- Sites
- 121
Conditions
As the registry lists them; a condition with its own page is linked.